Application of Garcinia Cambogia C
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- THE FIRST AFFILIATED HOSPITAL OF BENGBU MEDICAL COLLEGE
- Filing Date
- 2025-10-31
- Publication Date
- 2026-05-26
AI Technical Summary
Existing NLRP3 inflammasome inhibitors have shortcomings in terms of specificity, bioavailability, and safety, resulting in no drugs that directly target the NLRP3 inflammasome being approved for clinical use. Furthermore, the role of the natural compound Gar C in inflammation and related signaling pathways has not been fully studied.
Garcinia cambogia C (Gar C) is a natural flavonoid compound that inhibits the activation of NLRP3 inflammasomes in THP-1 cells and PBMCs of healthy volunteers. It is developed into an NLRP3 inflammasome inhibitor and can be used to prepare various dosage forms such as tablets and capsules for the prevention or treatment of NLRP3 inflammasome-related diseases.
Garcinia cambogia C significantly inhibits the release of IL-1β and caspase-1 p20 subunits at low doses, exhibiting good bioavailability and anti-inflammatory activity. It is effective in treating septic shock, acute liver injury, and acute peritonitis, and shows a specific inhibitory effect on the NLRP3 inflammasome, demonstrating significant clinical application prospects.
Smart Images
Figure CN122075474A_ABST